First CRISPR-based gene-editing therapy authorised
European Pharmaceutical Review
NOVEMBER 16, 2023
Side effects from treatment were similar to those associated with autologous stem cell transplants. No significant safety concerns were identified during the trials. Of these, 39 did not need a red blood cell transfusion for at least 12 months post-treatment.
Let's personalize your content